• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 7:05:31 AM ET
    $QTTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QTTB alert in real time by email
    8-K
    false000166199800016619982025-05-082025-05-08

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 08, 2025

     

     

    Q32 Bio Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-38433

    47-3468154

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    830 Winter Street

     

    Waltham, Massachusetts

     

    02451

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 781 999-0232

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, par value $0.0001 per share

     

    QTTB

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, Q32 Bio Inc. announced its financial results for the quarter ended March 31, 2025 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

    99.1

    Press Release issued by Q32 Bio Inc. on May 8, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Q32 BIO INC.

     

     

     

     

    Date:

    May 8, 2025

    By:

    /s/ Jodie Morrison

     

     

    Name:

    Title:

    Jodie Morrison
    Chief Executive Officer

     


    Get the next $QTTB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTTB

    DatePrice TargetRatingAnalyst
    2/11/2025$22.00 → $3.00Outperform → Market Perform
    BMO Capital Markets
    2/11/2025$20.00 → $4.00Overweight → Neutral
    Piper Sandler
    12/11/2024Buy → Neutral
    Guggenheim
    12/11/2024$95.00 → $16.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$90.00 → $22.00Strong Buy → Outperform
    Raymond James
    12/11/2024$68.00 → $9.00Outperform → Market Perform
    Leerink Partners
    12/6/2024$64.00Outperform
    BMO Capital Markets
    10/24/2024$90.00Strong Buy
    Raymond James
    More analyst ratings

    $QTTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Q32 Bio downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Q32 Bio from Outperform to Market Perform and set a new price target of $3.00 from $22.00 previously

      2/11/25 7:55:03 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Q32 Bio from Overweight to Neutral and set a new price target of $4.00 from $20.00 previously

      2/11/25 7:11:28 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio downgraded by Guggenheim

      Guggenheim downgraded Q32 Bio from Buy to Neutral

      12/11/24 10:44:38 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      11/14/24 5:46:10 PM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Q32 Bio Inc.

      SC 13G - Q32 Bio Inc. (0001661998) (Subject)

      11/13/24 4:05:13 PM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Q32 Bio Inc.

      SC 13G/A - Q32 Bio Inc. (0001661998) (Subject)

      10/25/24 6:06:25 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTTB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

      -- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass., May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alope

      5/8/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

      WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program. "The Fast Track designation granted by the FDA recogn

      4/30/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

      -- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA). "Dosing the first patients in both the Part A OLE and Part B of our SIGNAL-AA trial highlights our ongoing momentum in the clinical development of bempikibart as

      4/16/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTTB
    Financials

    Live finance-specific insights

    See more
    • Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

      -- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass., May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alope

      5/8/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

      WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signaling that is in development for the treatment of AA and currently being evaluated in a Phase 2 program. "The Fast Track designation granted by the FDA recogn

      4/30/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

      -- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA). "Dosing the first patients in both the Part A OLE and Part B of our SIGNAL-AA trial highlights our ongoing momentum in the clinical development of bempikibart as

      4/16/25 6:59:00 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTTB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Manke Isaac

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      2/27/25 6:05:43 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Laporte Kathleen

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      2/27/25 6:01:11 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and President Kalowski Lee was granted 53,250 shares (SEC Form 4)

      4 - Q32 Bio Inc. (0001661998) (Issuer)

      2/27/25 6:01:13 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $QTTB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Q32 Bio Inc.

      10-Q - Q32 Bio Inc. (0001661998) (Filer)

      5/8/25 7:11:49 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Q32 Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Q32 Bio Inc. (0001661998) (Filer)

      5/8/25 7:05:31 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Q32 Bio Inc.

      DEFA14A - Q32 Bio Inc. (0001661998) (Filer)

      4/29/25 7:15:34 AM ET
      $QTTB
      Biotechnology: Pharmaceutical Preparations
      Health Care